2. Signaling Pathways
  3. PROTAC
  4. PROTACs
  5. PROTACs Degrader

PROTACs Degrader

PROTACs Isoform Comparison

PROTACs Degraders (35):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-151902
    SJ988497 2595365-41-4 98.05%
    SJ988497 is a PROTAC JAK2 degrader. SJ988497 potently inhibits CRLF2-rearranged (CRLF2r) cell proliferation and degrades the CRBN neosubstrate GSPT1. SJ988497 consists of a Ruxolitinib (HY-50856) derivative, linker, and CRBN ligand Pomalidomide. SJ988497 can be used in the research of acute lymphoblastic leukemia (ALL).
    SJ988497
  • HY-156366
    SNX7886 2924557-42-4 99.97%
    SNX7886 is a potent protac degrader of CDK8/19. SNX7886 degrades CDK 8 and CDK 19 with 90% and 80% degradation in 293 cells, respectively.
    SNX7886
  • HY-160259
    VEGFR-2-IN-39 2353417-86-2 99.85%
    VEGFR-2-IN-39 (PROTAC-5) is a PROTAC targeting VEGFR-2 (IC50: 208.6 nM). VEGFR-2-IN-39 has low toxicity.VEGFR-2-IN-39 inhibits the proliferation of EA.hy926, one of HUVECs, in a concentration-dependent manner, with an IC50 of 38.65 µM.
    VEGFR-2-IN-39
  • HY-115718
    PZ703b 2471970-56-4 98.47%
    PZ703b is a Bcl-xl PROTAC degrader that induces apoptosis and inhibits cancer cell proliferation. PZ703b can be used for the research of bladder cancer research.
    PZ703b
  • HY-149862
    ARD-2051 2632305-17-8 98.19%
    ARD-2051 is a potent and orally active androgen receptor (AR) proteolysis-targeting chimera degrader. ARD-2051 achieves DC50 values of 0.6 nM for AR protein degradation in both the LNCaP and VCaP prostate cancer cell lines. ARD-2051 can be used for the research of prostate cancer.
    ARD-2051
  • HY-160415A
    WD6305 TFA 98.47%
    WD6305 TFA is a potent METTL3-targeted PROTAC degrader. WD6305 TFA selectively reduces the METTL3 and METTL14 complex. WD6305 TFA inhibits m6A modification and the proliferation of AML cells and promotes apoptosis. WD6305 TFA can be used for the research of leukemic.
    WD6305 TFA
  • HY-149843
    LC-MB12 2828438-38-4 99.23%
    LC-MB12 is an orally active PROTAC compound targets FGFR2 degradation with a DC50 of 11.8 nM. LC-MB12 contains BGJ398 (a FGFR2 inhibitor), PROTAC linker and CRBN.LC-MB12 inhibits FGFR2 signaling in gastric cancer cells and has anti-tumor activity.
    LC-MB12
  • HY-160502
    CST967 99.33%
    CST967 (Compound 17) is a USP7 PROTAC degrader, and increasing the PROTAC concentration can enhance the degradation rate of USP7. CST967 can be used in cancer research.
    CST967
  • HY-131865
    SJF-1521 2230821-40-4 99.20%
    SJF-1521 is a selective EGFR PROTAC degrader. SJF-1521 contains the EGFR inhibitor lapatinib (HY-50898). SJF-1521 can induce EGFR degradation in OVCAR8 cells.
    SJF-1521
  • HY-155361
    PROTAC BRD9 Degrader-7
    PROTAC BRD9 Degrader-7 is an orally active and selective degrader of BRD9 with a DC50 of 1.02 nM. PROTAC BRD9 Degrader-7 has superior oral activity with a Cmax of 3436.95 ng/mL.
    PROTAC BRD9 Degrader-7
  • HY-161173
    PROTAC SOS1 degrader-5 2836273-61-9
    PROTAC SOS1 degrader-5 (compound 4) is a potent PROTAC SOS1 degrader, with the DC50 of 13 nM. PROTAC SOS1 degrader-5 strongly inhibits NCI-H358 cells proliferation with an IC50 of 5 nM.
    PROTAC SOS1 degrader-5
  • HY-148521
    PROTAC FLT3/CDK9 degrader-1
    PROTAC FLT3/CDK9 degrader-1 is a potent FLT3 and CDK9 dual PROTAC degrader. PROTAC FLT3/CDK9 degrader-1 induces apoptosis and effective degradation of target proteins FLT3 and CDK9. PROTAC FLT3/CDK9 degrader-1 has the potential for the research of FLT3-ITD mutated AML.
    PROTAC FLT3/CDK9 degrader-1
  • HY-153880
    KRAS degrader-1 2795275-59-9
    KRAS degrader-1 (compound 1) is a potent KRAS degrader. KRAS degrader-1 target specific proteins for degradation through the autophagy-lysosomal degradation pathway.
    KRAS degrader-1
  • HY-149845
    PROTAC GSK-3β Degrader-1
    PROTAC GSK-3β Degrader-1 (compound 1) is a degrader targets GSK-3β degradation with an IC50 value of 833 nM. PROTAC GSK-3β Degrader-1 contains SB-216763 (a GSK-3β inhibitor), a PEG linker and a CRBN (E3 ligase liand). PROTAC GSK-3β Degrader-1 reduces the neurotoxicity induced by Aβ25-35 peptide and CuSO4. PROTAC GSK-3β Degrader-1 can be used to research in Alzheimer's disease.
    PROTAC GSK-3β Degrader-1
  • HY-149295
    PROTAC ERα Degrader-4 2521299-80-7
    PROTAC ERα Degrader-4 is a highly potent and selectivePROTAC ERα degrader (Ki: 5.08 μM). PROTAC ERα Degrader-4 contains OBHSAs, linker and E3 ligase ligands. PROTAC ERα Degrader-4 shows excellent cell inhibitory and ERα degradation activity against Tamoxifen-sensitive and -resistant ER+ breast cancer (BC) cells and ERα-mutated BC cells. PROTAC ERα Degrader-4 can induce apoptosis and can be used for cancer research.
    PROTAC ERα Degrader-4
  • HY-162362
    MS8709
    MS8709 (10), a potential anticancer therapeutic, is a first-in-class G9a/GLP PROTAC degrader. MS8709 (10) is based on G9a/GLP inhibitor UNC0642 and recruits the von Hippel Lindau (VHL) E3 ligase (Red: G9a/GLP inhibitor UNC0642; Blue: VHL ligand; Black: linker).
    MS8709
  • HY-155102
    PROTAC TG2 degrader-2
    PROTAC TG2 degrader-2 (compound 7) is a selective, competitive degrader targeting Transglutaminase 2 (TG2), with Kd > 100 μM. PROTAC TG2 degrader-2 inhibits the cell migration and decreases the level of TG2 in ovarian cancer cells. PROTAC TG2 degrader-2 can be used for ovarian cancer study.
    PROTAC TG2 degrader-2
  • HY-157426
    GSPT1 degrader-3
    GSPT1 degrader-3 (Pro-2) is a CRBN-based PROTAC degrader for BRD, with a DC50 of 21.1 nM (4h).
    GSPT1 degrader-3
  • HY-162241
    SJH1-62B
    SJH1-62B is a proteolysis targeting chimera (PROTAC) that can target the androgen receptor (AR).
    SJH1-62B
  • HY-161167
    MM-02-08
    MM-02-08 is the potent BRD4 degrader and binds to DDB1.
    MM-02-08